Content
Some custom products might not be readily available for the business to buy, so the business has to go through the process of custom ordering it or making it. One-way sensitivity analyses were performed on the main model for ADDITION-UK with varying treatment costs, utility decrements, and discount rates using the 30-year simulation data. The range for the discount rate (0%–5%) was guided by NICE guidelines suggesting a discount bookkeeping for startups rate of 3.5% as base case and 1.5% in sensitivity analyses [42]. The range for utility decrements and unit costs (−20% to +20%) was guided by the coefficient of variation of parameter estimates that averaged approximately 8% to 12% in the data sources from which the input parameters were taken [36], [39]. The diagnosis of diabetes in routine care settings occurs on average a couple of years after physiological onset [12].
There is uncertainty about the costs and the cost effectiveness of early intensive multifactorial treatment as delivered in the ADDITION trial. On the basis of electronic primary care records of a subsample of the trial cohort, we analyzed the incremental costs of delivered intensive treatment in ADDITION-Cambridge. Following an iterative framework of decision making in health care, we used these empirical cost estimates to update the previously published cost-effectiveness analysis for ADDITION-UK and present estimates for ADDITION-Cambridge.
Definition of Incremental Costs
In the initial long-term cost-effectiveness analysis we also erroneously presumed that the mean costs for additional medication would be incurred until the end of the 10-, 20-, and 30-year simulation time horizon independently of individual simulated deaths of participants [17]. In this study, we took the more plausible assumption that costs for extra medication will occur until a person dies or reaches the end of the simulated time horizon. Applying this assumption to the previous cost-effectiveness analyses would have led to ICER point estimates of around £83,000/QALY, £32,000/QALY, and £30,000/QALY for a 10-, 20-, and 30-year simulation time horizon, respectively. The decrease in the ICER in our study can be explained by the lower frequency of extra consultations compared with the per-protocol assumed costs in the ADDITION-Cambridge sample (see Table 1).
Manufactures look at incremental costs when deciding to produce another product. Often times new products can use the same assembly lines and raw materials as currently produced products. Unfortunately, most of the time when manufacturers take on new product lines there are additional costs to manufacture these products. Management must look at these incremental costs and compare them to the additional revenue before it decides to start producing the new product. Revisiting the previously developed robust evaluation framework [17] with the empirical trial–informed cost estimates shows that the intervention has a moderate likelihood of being cost-effective over a time horizon of 30 years, assuming the higher UK NICE WTP threshold of £30,000/QALY. Our sensitivity analyses also indicated that the intervention might be cost effective with most recent prices.
Case Study1
In Cambridge, primary care surgeries received funding for more frequent contacts between patients and practitioners. An initial practice-based academic detailing session conducted by a local diabetologist and an academic GP and interactive practice-based audit and feedback sessions were organized around 6 and 14 months after the initial education session and annually thereafter. Surgery staff received theory-based education materials to hand over to patients, and participants were encouraged to initiate lifestyle changes, to adhere to medication schemes, to self-monitor blood glucose levels if given a glucometer by their practice, and to attend annual health checks. The curriculum focuses on lifestyle changes and medication adherence using theories of efficient goal setting and self-efficacy. In addition, in the first year after diagnosis, patients were offered bimonthly appointments with a nurse or a GP in a community peripatetic clinic, and 4-monthly thereafter. There is uncertainty about the cost effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening.
Models accounted for observation years being clustered into patients and patients being clustered into primary care surgeries (three-level random intercept model) and were adjusted for age, sex, and HbA1c level at diagnosis. We also introduced an interaction term between the year after diagnosis and the treatment status to capture potential trends over time. In a second step, using the same statistical methods, we estimated the total annual incremental costs.
Routine Care versus Intensive Treatment
The Department of Energy (DOE) prepared an incremental cost analysis of current costs across classes of street vehicles. The variation across vehicle makes and models and the lack of a directly comparable vehicle in most cases makes it difficult to directly determine the incremental cost of vehicle electrification technologies by comparing two actual vehicles for sale. As costs of batteries, fuel cells, and hydrogen tanks decrease over time, DOE may update the analysis. Another important aspect of cost evaluation in supply chains is the concept of incremental costs.
Recent Comments